Sorrento Therapeutics

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Sorrento Therapeutics
TickerSRNE
CIK #0000850261
CUSIP83587F202
SectorTrade & Services
IndustryServices-Commercial Physical & Biological Research
Phone8582103700
Address6042 Cornerstone Ct West Suite B
San Diego, CA 92121
Source [EDGAR]
Market Cap, 13F ($MM)
80064048032016002011201320152018
Business

Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries (collectively, the "Company", "we", "us" and "our") is a clinical stage and commercial biopharma company focused on delivering innovative and clinically meaningful therapies to patients and their families to address unmet medical needs. We also have programs assessing the use of our technologies and products in autoimmune, inflammatory and neurodegenerative diseases.

At our core, we are an antibody-centric company and leverage our proprietary G-MAB™ library and targeted delivery modalities to generate the next generation of cancer therapeutics. Our fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, CTLA-4, c-MET, VEGFR2, CCR2 and CD137 among others.

Our vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary chimeric antigen receptor T-cell therapy ("CAR-T"), dimeric antigen receptor T-cell therapy ("DAR-T"), antibody drug conjugates ("ADCs") as well as bispecific antibody approaches. We acquired Sofusa®, a revolutionary drug delivery system, in July 2018, which delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. Additionally, our majority owned subsidiary, Scilex Holding Company ("Scilex Holding"), acquired the assets of Semnur Pharmaceuticals, Inc. ("Semnur") in March 2019. Semnur's SEMDEXATM (SP-102) compound has the potential to become the first FDA-approved epidural steroid product for the treatment of sciatica.

CIK Filing 2011 - 2021
[0000850261] 10-K
[0000850261] 10-Q
[0000850261] 3
[0000850261] 4
[0000850261] 5
[0000850261] 8-K
[0000850261] D
[0000850261] SC 13D
[0000850261] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Oaktree Capital Management LP Sorrento Therapeutics Inc [2019-09-25] 2.2
OPKO Health Inc Sorrento Therapeutics Inc [2019-05-09] 0.0
Ally Bridge Group Capital Partners II LP Sorrento Therapeutics Inc [2019-02-13] 0.4
BlackRock Inc Sorrento Therapeutics Inc [2019-02-08] 6.2
Magnum Opus 2 International Holdings Ltd Sorrento Therapeutics Inc [2018-07-13] 7.0
Magnum Opus 2 International Holdings Ltd Sorrento Therapeutics Inc [2018-07-13] 5.0
Famous SINO Ltd Sorrento Therapeutics Inc [2018-06-27] 5.0
Famous SINO Ltd Sorrento Therapeutics Inc [2018-06-27] 7.0
China in Shine Investment Ltd Sorrento Therapeutics Inc [2018-06-22] 7.0
Top Path Asia Ltd Sorrento Therapeutics Inc [2018-06-22] 5.0
China in Shine Investment Ltd Sorrento Therapeutics Inc [2018-06-22] 5.0
Hongguo International Holdings Ltd Sorrento Therapeutics Inc [2018-06-22] 5.0
Top Path Asia Ltd Sorrento Therapeutics Inc [2018-06-22] 7.0
Hongguo International Holdings Ltd Sorrento Therapeutics Inc [2018-06-22] 7.0
JI Henry Sorrento Therapeutics Inc [2018-01-26] 5.9
Ally Bridge Group Capital Partners II LP Sorrento Therapeutics Inc [2017-07-10] 11.0
Xianjian Advanced Technology Ltd Sorrento Therapeutics Inc [2017-05-15] 4.4
Asia Pacific Medtech BVI Ltd Sorrento Therapeutics Inc [2017-05-01] 12.8
Wildcat Capital Management LLC Sorrento Therapeutics Inc [2017-02-14] 5.3
Sorrento Therapeutics Inc Medovex Corp [2016-12-09] 0.0
Frejoy Investment Management Co Ltd Sorrento Therapeutics Inc [2016-06-24] 0.0
Henan Yulin Green Engineering Co Ltd Sorrento Therapeutics Inc [2016-06-23] 0.0
ABG SRNE Ltd Sorrento Therapeutics Inc [2016-06-10] 0.6
Yuhan Corp Sorrento Therapeutics Inc [2016-05-09] 5.0
Wildcat Capital Management LLC Sorrento Therapeutics Inc [2016-04-18] 6.5
Wildcat Capital Management LLC Sorrento Therapeutics Inc [2016-04-18] 11.0
Sorrento Therapeutics Inc Nantkwest Inc [2016-02-17] 6.92
Cormorant Global Healthcare Master Fund LP Sorrento Therapeutics Inc [2015-05-26] 5.4
Soon-Shiong Patrick Sorrento Therapeutics Inc [2014-12-24] 19.9
Aisling Capital III LP Sorrento Therapeutics Inc [2014-05-23] 6.3
[2012-01-25] None
Form 3/4/5 Filer 2011-2021
Asghar Najjam
JI Henry
Janda Kim
Shah Jaisim
Shao Jiong
Smith Robin L
WU Yue Alexander
Followwill Dorman
Lee Edgar
Lemus David
Zeldis Jerome B
Ally Bridge LB Healthcare Master Fund Ltd
ABG Ii-So Ltd
ABG Innovation-So Ltd
ABG Management Ltd
ABG SRNE Ltd
Ally Bridge Group Capital Partners II LP
Ally Bridge Group Innovation Capital Partners III LP
Ally Bridge LB Management Ltd
Li Bin
YU Fan
NG George K
Ferrigno Dean
Asia Pacific Medtech BVI Ltd
GU Nana
Deming David H
Herde Kevin
SU Jeffrey
Toledano Miranda Jayne
Marth William S
Ebersole Douglas O
Chan Soon-Shiong Family Foundation
Soon-Shiong Patrick
MP 13 Ventures LLC
Cambridge Equities LP
UY George
MIAO Zhenwei
Durand Mark
Vincent Richard G
Royal Mike
Levitt Daniel J
Gallagher CAM
Salka Michael Scott
Singh AMAR
OPKO Health Inc
Afting Ernst-Guenter
Trieu Vuong
Webb David Ritchie
Lockshin Curtis
Tang-Liu Diane D S
Scifres Donald R
Halpryn Glenn L
Hsiao Jane PH D
MM Shares Owned of 122.3 MM Total
Firm Period DFND Voting Shares
BlackRock Inc. [2020-09-30] SOLE 14.7 15.0
State Street Corp [2020-09-30] DFND 10.8 11.7
Vanguard Group Inc [2020-09-30] SOLE 0.0 10.5
Cormorant Asset Management, LLC [2020-09-30] DFND 6.0 6.5
Susquehanna International Group LLP [2020-09-30] DFND 0.6 6.0
Jane Street Group LLC [2020-09-30] DFND 1.4 3.3
Geode Capital Management LLC [2020-09-30] DFND 3.1 3.1
Morgan Stanley [2020-09-30] DFND 2.0 2.7
Northern Trust Corp [2020-09-30] DFND 0.2 2.6
Citadel Advisors LLC [2020-09-30] DFND 1.6 1.6
Schwab Charles Investment Management Inc [2020-09-30] SOLE 1.4 1.4
Nuveen Asset Management LLC [2020-09-30] DFND 1.2 1.2
Goldman Sachs Group Inc [2020-09-30] DFND 1.2 1.2
Wells Fargo & Co/Mn [2020-09-30] DFND 0.6 0.8
Bank of New York Mellon Corp [2020-09-30] DFND 0.7 0.8
Coatue Management LLC [2020-09-30] DFND 0.8 0.8
D. E. Shaw & Co., Inc. [2020-09-30] DFND 0.6 0.6
Sabby Management LLC [2020-09-30] DFND 0.0 0.6
Millennium Management LLC [2020-09-30] SOLE 0.6 0.6
Vanguard Group Inc [2020-09-30] DFND 0.0 0.6
JPMorgan Chase & Co [2020-09-30] DFND 0.6 0.6
California Public Employees Retirement System [2020-09-30] SOLE 0.5 0.5
Credit Suisse AG [2020-09-30] DFND 0.4 0.4
Barclays PLC [2020-09-30] SOLE 0.4 0.4
Wolverine Trading LLC [2020-09-30] DFND 0.0 0.3
California State Teachers Retirement System [2020-09-30] SOLE 0.3 0.3
Caption Management LLC [2020-09-30] SOLE 0.3 0.3
State of Wisconsin Investment Board [2020-09-30] SOLE 0.3 0.3
AllianceBernstein LP [2020-09-30] DFND 0.3 0.3
Rafferty Asset Management LLC [2020-09-30] SOLE 0.3 0.3
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com